Market Overview

UPDATE: Barclays Begins Coverage on Cerner and Advisory Board

Share:
Related CERN
Barron's Picks And Pans: Interpublic, Zimmer Biomet And More
Benzinga's Top Downgrades
Related ABCO
Benzinga's Top Upgrades
Mid-Afternoon Market Update: US Stocks Turn Higher; Avis Budget Shares Drop On Weak Outlook

Barclays Wednesday reports includes a note from analyst Eric Percher for coverage initiation on Cerner (NASDAQ: CERN) and The Advisory Board Company (NASDAQ: ABCO) with an Overweight rating for each company. Price target of $79.

Percher notes, "Given our findings that the transition to value-based reimbursement and implementation of population health tools on a large scale will be at least a five- to seven-year journey, we favor companies that either provide services which will enable the journey itself or have demonstrated opportunities to drive growth outside of population health offerings. We believe no company is better positioned to advise hospital leadership than Advisory Board and Cerner's diversified growth strategy should drive double-digit growth even absent meaningful population health contributions."

ABCO closed Tuesday at $66.79 and opened Wednesday morning at $67. CERN closed previous session at $61.86 and opened at $61.94.

Latest Ratings for CERN

DateFirmActionFromTo
Feb 2016Goldman SachsDowngradesBuyNeutral
Feb 2016Evercore ISI GroupDowngradesBuyHold
Feb 2016UBSMaintainsBuy

View More Analyst Ratings for CERN
View the Latest Analyst Ratings

Posted-In: BarclaysPrice Target Initiation Analyst Ratings

 

Related Articles (ABCO + CERN)

View Comments and Join the Discussion!